Tigecycline's Core Spectrum
Tigecycline, a glycylcycline antibiotic, covers many multidrug-resistant (MDR) Gram-positive, Gram-negative, and anaerobic bacteria. It inhibits bacterial protein synthesis by binding the 30S ribosomal subunit. Key strengths include activity against MRSA, vancomycin-resistant Enterococcus (VRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, Acinetobacter baumannii, and Bacteroides fragilis. It lacks strong coverage against Pseudomonas aeruginosa and Proteus species due to efflux pumps and poor serum levels.[1][2]
How Tigecycline Stacks Up Against Tetracyclines
Tigecycline overcomes tetracycline resistance via efflux and ribosomal protection, unlike older tetracyclines (e.g., doxycycline, minocycline). It retains potency against tetracycline-resistant strains of Staphylococcus, Streptococcus, and Enterobacteriaceae. Minocycline edges it out on some community MRSA isolates, but tigecycline handles more MDR Gram-negatives.[1][3]
Comparison with Carbapenems Like Meropenem
Tigecycline matches meropenem against many ESBL-producers and anaerobes but falls short on Pseudomonas, Proteus, and some non-fermenters where meropenem excels. Meropenem covers a broader Gram-negative range; tigecycline is preferred for MDR Acinetobacter or when carbapenem resistance emerges. Both handle anaerobes well, but tigecycline avoids some beta-lactamase issues.[2][4]
Versus Beta-Lactams and Cephalosporins
Against ceftazidime or piperacillin-tazobactam, tigecycline covers more MDR Gram-positives (e.g., MRSA) and anaerobes, but beta-lactams outperform on Pseudomonas, Enterobacter cloacae, and Proteus. Tigecycline resists many beta-lactamases, making it useful in polymicrobial intra-abdominal infections where resistance patterns vary.[1][2]
Matchup with Fluoroquinolones Like Ciprofloxacin
Ciprofloxacin beats tigecycline on Pseudomonas, Proteus, and some urinary pathogens due to tigecycline's MIC creep and low urine penetration. Tigecycline wins on MDR Gram-positives and anaerobes, where quinolone resistance is common. Overlap exists on E. coli and Klebsiella, but tigecycline handles more resistant subsets.[3][4]
Against Vancomycin and Daptomycin for Gram-Positives
Tigecycline covers VRE and MRSA comparably to vancomycin or daptomycin, often with lower MICs against some VRE faecium strains. Linezolid competes closely on enterococci and staphylococci. Tigecycline adds Gram-negative/anaerobic breadth, but vancomycin remains first-line for serious Gram-positive infections without those needs.[1][2]
Key Gaps: What Tigecycline Misses
No reliable activity against Pseudomonas aeruginosa, Burkholderia, Stenotrophomonas, or Proteus/Providencia (due to efflux and low concentrations). Weak on Streptococcus pneumoniae and Haemophilus influenzae compared to beta-lactams or macrolides. Avoid for bacteremia or urinary infections—low serum (0.6 mcg/mL peak) and negligible urine levels limit efficacy.[2][4]
Clinical Use Cases and Resistance Trends
Tigecycline shines in complicated skin/skin-structure infections (cSSSI), intra-abdominal infections (cIAI), and hospital-acquired pneumonia against MDR pathogens. Resistance rises via efflux pumps (e.g., Tet(A)) in Enterobacteriaceae. Guidelines (IDSA) recommend it as second-line for MDR Acinetobacter cIAI but caution against monotherapy in severe infections.[1][5]
Sources
[1]: FDA Tigecycline Label
[2]: Clinical Microbiology Reviews - Tigecycline Spectrum
[3]: Antimicrobial Agents and Chemotherapy - Glycylcycline Comparisons
[4]: Journal of Antimicrobial Chemotherapy - Tigecycline vs. Others
[5]: IDSA Guidelines on MDR Gram-Negatives